XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 1,466,652 $ 923,529 $ 8,379,062 $ 2,299,669
Acquired in-process research and development 80,537,551 0 80,537,551 0
General and administrative 4,258,178 1,084,057 10,515,088 2,741,652
Transaction costs 0 0 5,765,407 0
Change in fair value of contingent consideration 70,000 0 (750,000) 0
Total operating expenses 86,332,381 2,007,586 104,447,108 5,041,321
Loss from operations (86,332,381) (2,007,586) (104,447,108) (5,041,321)
Other income (expenses):        
Loss on sale of NTN assets 0 0 (9,648,173) 0
Other income (expense), net 277,069 (12,559) 252,318 (31,482)
Total other income (expenses), net 277,069 (12,559) (9,395,855) (31,482)
Net loss (86,055,312) (2,020,145) (113,842,963) (5,072,803)
Series A convertible preferred stock dividend 0 0 (7,806) 0
Net loss attributable to common stockholders $ (86,055,312) $ (2,020,145) $ (113,850,769) $ (5,072,803)
Net loss per common share - basic (in dollars per share) $ (1.70) $ (0.11) $ (2.82) $ (0.29)
Net loss per common share - diluted (in dollars per share) $ (1.70) $ (0.11) $ (2.82) $ (0.29)
Weighted average number of shares outstanding - basic (in shares) 50,543,982 17,626,806 40,362,440 17,570,973
Weighted average number of shares outstanding - diluted (in shares) 50,543,982 17,626,806 40,362,440 17,570,973